Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Sirtex Doses First Patient in China Trial of Microsphere Radiation Therapy

publication date: Oct 13, 2021

Sirtex Medical, a division of China Grand Pharma and Healthcare, started a China trial of its selective internal radiation therapy in patients with hepatocellular carcinoma (HCC). One year ago, Sirtex filed an NDA in China for its SIR-Spheres® Y-90 resin microspheres, a targeted radiation therapy, for liver metastases from colorectal cancer. The Y-90 resin microspheres are designed to accumulate in the liver, where they deliver a 40-times larger dose of radiation without affecting normal tissue. In 2018, China's CDH Holding paid $1.9 billion to acquire Sirtex. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China